Fairmount Funds Management LLC - Insider Trading & Ownership

Entity
Company
Location
200 Barr Harbor Drive, Suite 400, West Conshohocken, PA
Summary
The estimated value of insider holdings of Fairmount Funds Management LLC is at least $347M dollars as of November 21, 2024. Fairmount Funds Management LLC is the Director of Apogee Therapeutics, Inc. and owns shares of Apogee Therapeutics, Inc. (APGE) stock worth about $80.1M. Fairmount Funds Management LLC is the Director, 10%+ Owner of Oruka Therapeutics, Inc. and owns shares of Oruka Therapeutics, Inc. (ORKA) stock worth about $77.6M. Fairmount Funds Management LLC is the Director, 10%+ Owner of Viridian Therapeutics, Inc.\DE and owns shares of Viridian Therapeutics, Inc.\DE (VRDN) stock worth about $64.6M. Fairmount Funds Management LLC is the Director of Cogent Biosciences, Inc. and owns shares of Cogent Biosciences, Inc. (COGT) stock worth about $46.7M. Fairmount Funds Management LLC is the Director of Dianthus Therapeutics, Inc. /DE/ and owns shares of Dianthus Therapeutics, Inc. /DE/ (DNTH) stock worth about $42.4M. Fairmount Funds Management LLC is the Director of Zenas BioPharma, Inc. and owns shares of Zenas BioPharma, Inc. (ZBIO) stock worth about $32.2M. Fairmount Funds Management LLC is the Director of Spyre Therapeutics, Inc. and owns shares of Spyre Therapeutics, Inc. (SYRE) stock worth about $3.43M.
All Insider Reports
All Insider Reports

Ownership of Fairmount Funds Management LLC

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
APGE Apogee Therapeutics, Inc. Director $80.1M Jun 5, 2024
ORKA Oruka Therapeutics, Inc. Director, 10%+ Owner $77.6M Nov 19, 2024
VRDN Viridian Therapeutics, Inc.\DE Director, 10%+ Owner $64.6M +$40M +163% Sep 13, 2024
COGT Cogent Biosciences, Inc. Director $46.7M Jun 10, 2024
DNTH Dianthus Therapeutics, Inc. /DE/ Director $42.4M Sep 27, 2024
ZBIO Zenas BioPharma, Inc. Director $32.2M +$5.1M +18.8% Sep 12, 2024
SYRE Spyre Therapeutics, Inc. Director $3.43M May 14, 2024

Insider Transactions Reported by Fairmount Funds Management LLC:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.